Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program (NCT04650269), a na phase 4 study. The primary outcome is Percentage of Participants With HIV Viral Load Suppression.

2. Clinical Question

The study’s stated purpose is to examine whether offering HIV medicine right away at the syringe services program helps participants start and remain in HIV care, including achieving no detectable HIV in blood. The primary endpoint addresses viral suppression at the six-month point. That is a focused measure of virologic status, but it does not by itself describe every aspect of starting or remaining in care. The registry lists HIV viral load suppression as a secondary outcome as well, but does not provide a separate numerical result for it.

Because the study has no randomized or concurrent control group, its primary question is descriptive: what suppression outcome was recorded among participants in this care pathway? It is not a direct estimate of how the pathway compares with a different service model. The registry record also does not report the endpoint’s numerical result, so any conclusion about the observed outcome must remain open.

3. Trial Design

This completed Phase 4 study, NCT04650269, is listed as a single-group study sponsored by the University of Miami. Enrollment was 27. Allocation is listed as not applicable, and masking as none. The record does not describe random assignment or a separately assigned control group. Accordingly, the design is not a like-for-like comparison between alternative care strategies.

The arm description lays out a care sequence: participants in the Rapid ART group receive HIV care including Biktarvy at the syringe services program for six months, followed by six months of standard care at a traditional clinic. The listed interventions are Biktarvy 50Mg-200Mg-25Mg Tablet and HIV care. The registry’s stated primary outcome is viral suppression at six months, placing the endpoint at the end of the onsite portion of the described schedule. The record does not report a primary endpoint result at the end of the subsequent clinic-care period.

The registry lists a study start date of 2021-03-04, a primary completion date of 2023-12-31, and a status of completed. These dates describe the study record, not the timing of an individual participant’s measurements. The registry does not report the protocol details needed to determine how participants entered the study, how often outcomes were assessed, or how care was delivered in practice beyond the arm description.

With a single group, observed outcomes can describe participants receiving the pathway but cannot separate the pathway’s effect from other influences on those outcomes. Changes over time, differences in participants’ circumstances, and other factors could also contribute. The registry record does not report a comparison strategy or an adjusted analysis that would address such influences. The study therefore offers a report on implementation in this setting, rather than a controlled estimate of comparative effectiveness.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Data was not collected for those participants that were lost to follow-up or death due to COVID pandemic

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With HIV Viral Load Suppression, measured over 6 months.

The primary endpoint is the percentage of participants with HIV viral load suppression at six months. The registry defines suppression as less than 200 copies/ml in participants’ blood. This is a binary outcome at the participant level: a measurement is either below the stated threshold or it is not. The endpoint is not a measure of the exact viral load value, the amount of change from baseline, or every aspect of engagement in care.

Viral suppression is used as a clinical-trial endpoint because it gives a specified way to summarize virologic status at a particular follow-up point. A threshold makes the outcome interpretable as the number or proportion of participants meeting a defined criterion. The endpoint can therefore describe whether participants reached that criterion at six months, provided the underlying measurements and the population included in the calculation are clear.

The registry’s brief summary also refers to having no detectable HIV in blood. That wording should not be treated as identical to the formal primary endpoint definition: the endpoint is explicitly defined using the less-than-200-copies/ml threshold. The primary endpoint result itself is not reported in the registry record. The record also says that data were not collected for participants lost to follow-up or death due to the COVID pandemic. Without the outcome count, denominator, and handling of those participants, the percentage and its precision cannot be evaluated from the registry information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a binary primary outcome: whether a participant’s viral load is below the stated threshold at six months. For a binary endpoint, a basic summary is the number meeting the criterion and the number assessed, expressed as a percentage. The registry record names the percentage as the primary measure but does not report the count, denominator, or numerical percentage. Those omissions prevent a direct reading of the observed endpoint from this record.

What an estimate describes

An observed percentage describes the participants included in its calculation. It does not automatically describe all enrolled participants, all people eligible for the study, or people in other settings. The distinction depends on the analysis population and on how missing measurements are handled. Here, the record says that data were not collected for participants lost to follow-up or death due to the COVID pandemic, but it does not state how many participants were affected or how the endpoint denominator was determined.

A confidence interval is a statistical summary of uncertainty around an estimated quantity, under a model and its assumptions. For a proportion, the interval reflects that the observed participants are only one possible realization of outcomes in a broader population. A narrow interval generally indicates greater precision than a wide interval, but precision does not remove biases due to missing data, selection, measurement, or study design. No confidence interval for the primary endpoint is reported in the registry record.

Why the design affects interpretation

Randomized comparisons are designed to make groups comparable on average at the start of a study. This trial has one group and no assigned comparator, so that type of between-group contrast is unavailable. A change over time, if reported, would still not isolate the effect of the care pathway: participants may experience other changes that influence the outcome. The registry record does not report an adjusted comparative analysis. A descriptive result can be useful for characterizing the group and implementation setting, but it answers a different question from a controlled treatment comparison.

Masking is listed as none. Masking can reduce the influence of knowledge about assigned treatment on some aspects of study conduct or assessment. For a laboratory viral-load measure, the relevance depends on the measurement and analysis procedures, which are not described. The absence of masking should be reported as a design feature without assuming its impact on this particular endpoint.

Planning illustrations and power

The sample-size section accompanying the page presents planning illustrations based on the observed effect, rather than the trial’s own design. The stated assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. For time-to-event tables, the illustration gives the total number of events; other tables give participants per arm.

These assumptions describe hypothetical planning scenarios, not the actual design of this single-group trial. In particular, equal allocation between two arms does not turn the study into a two-arm comparison. A planning illustration is not observed power, and it is not evidence that the study had a particular chance of detecting an effect. The registry record does not report the trial’s own sample-size justification or a prospective design calculation. The numerical planning results are presented in the sample-size section and are not repeated.

Over-dispersion and model choice

In general, over-dispersion means that observed variability is greater than a statistical model expects. It can make standard errors too small if a model assumes less variability than the data contain. The appropriate response depends on the outcome, data structure, and analysis plan; it cannot be inferred just from a study’s title or endpoint. The registry record does not report an analysis model, a dispersion estimate, or an adjustment for over-dispersion. The endpoint is described as a participant count or percentage, but that alone does not establish which model, if any, was used.

More broadly, an analysis plan can specify the target population, endpoint definition, treatment of missing observations, statistical model, and uncertainty summaries before results are examined. These details support transparent interpretation and reduce ambiguity about how results were selected or calculated. The registry lists three outcome measures and no analyses, but does not report a statistical analysis plan in the record. The absence of reported methods does not show that no analyses were conducted; it means the methods cannot be assessed from this registry record.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Rapid ART Group")
n      <- c(16)
events <- c(11)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Rapid ART Group  16  11  68.8  41.3  89.0  44.4  85.8  44.0  85.8

11. Multiplicity, Missing Data and Analysis Populations

Multiplicity arises when a study examines more than one outcome, time point, subgroup, or statistical comparison. Repeated testing can increase the chance of finding an apparently notable result by chance, so an analysis plan may specify a primary outcome and how additional analyses will be interpreted or adjusted. This registry identifies the percentage of participants with HIV viral load suppression as the primary outcome and lists three outcome measures overall. It also lists the same viral suppression title twice among secondary outcomes. The record does not explain whether these entries refer to distinct assessments or how multiplicity was handled.

No analysis results or statistical analysis plan are reported in the registry record. It is therefore not possible to determine which comparisons were tested, whether any adjustment was planned, or how secondary findings should be prioritized. The primary endpoint is clearly named, but that does not by itself resolve the interpretation of multiple outcomes or analyses.

For missing data, the registry states that data were not collected for participants lost to follow-up or death due to the COVID pandemic. It does not report the number of affected participants, the number assessed at six months, the endpoint denominator, or whether missing outcomes were excluded, imputed, or handled in another way. Missingness can affect interpretation if participants without measurements differ systematically from those with measurements. Without details on the extent and handling of missingness, the direction or size of any resulting bias cannot be determined.

The record does not describe an intention-to-treat population, a per-protocol population, or other analysis populations. Those definitions are not reported in the registry record. This matters because a reported percentage can change depending on which participants are included and how missing measurements are treated. The record’s enrollment count alone does not establish the number contributing data to the primary endpoint.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: death (11.1%).

The safety record lists the Rapid ART Group with 27 participants at risk for serious adverse events and 3 participants affected. It also lists 27 at risk for other adverse events and 0 affected. The serious adverse event terms include death, reported at 11.1%, and the death count is listed as 3. These entries describe the registry’s safety reporting for this group.

They should not be read as evidence that the care pathway caused the events. The study has no separate comparison group, and the registry information does not report event timing, individual circumstances, causal attribution, or the method used to collect adverse-event information. It also does not provide enough detail to determine how the death term relates to each reported serious adverse event beyond the entries shown. The record notes that data were not collected for participants lost to follow-up or death due to the COVID pandemic; it does not clarify how that statement relates to safety ascertainment.

These counts are not a comparative rate, nor do they establish the likelihood of an event in another population or setting. A safety interpretation needs the event definitions, follow-up period, attribution procedures, and context for the participants at risk. Those details are not reported in the registry record. The figures should therefore be presented as registry-reported safety entries, not as a causal conclusion or a basis for medical advice.

13. What the Result Does, and Does Not, Mean

The record describes an implementation-focused study of onsite rapid ART initiation among people who inject drugs living with HIV at a syringe services program. It specifies a six-month primary endpoint for viral suppression and defines the threshold as less than 200 copies/ml in blood. The described care pathway includes onsite HIV care and Biktarvy, followed by standard care at a traditional clinic.

What the posted record does not provide is the numerical result for the primary endpoint. It does not report how many participants met the threshold, the denominator used, or an uncertainty interval. As a result, readers cannot determine the observed suppression percentage or its precision from this registry information. The stated study purpose is not a substitute for an outcome result.

Even if a numerical proportion is available elsewhere on the page, the single-group design would limit what can be concluded from it. An observed outcome in this group would not establish what would have occurred under another care model. There is no separately assigned comparator in the registry design, and the study does not provide a like-for-like control comparison. Findings would describe the participants and setting studied rather than quantify a causal difference between treatment strategies.

The missing-data note also matters. The registry says outcome data were not collected for participants lost to follow-up or death due to the COVID pandemic. Without a reported count, endpoint denominator, and handling approach, it is not possible to judge whether the observed data represent all enrolled participants or how missingness might influence the result. The safety entries likewise do not establish causation or comparative risk.

Accordingly, the study’s design and endpoint can be described, but the registry record does not support a numerical claim about the primary outcome or a comparative treatment conclusion. The record also does not report the details needed to assess the statistical analysis plan, sample-size justification, or analysis populations.

14. Why This Trial Matters Statistically

This study raises a statistically important question about how to evaluate a care pathway delivered in a community setting. The primary endpoint is concrete and time-specific: viral suppression at six months using a defined threshold. Naming the threshold and assessment point helps readers understand what the endpoint represents and keeps the result distinct from broader aims such as starting and remaining in care.

The design also illustrates the difference between implementation description and comparative evaluation. A single-group study can document the outcomes recorded among participants receiving a service model. Without a separate comparison group, however, the outcome cannot isolate the pathway’s contribution from other influences. That distinction is important when a study’s purpose is framed around whether an approach helps participants achieve an outcome.

Missing measurements are another central issue. The registry notes that data were not collected for participants lost to follow-up or death due to the COVID pandemic. Transparent reporting of the number with outcome data, the endpoint denominator, and the missing-data approach is necessary to understand whom a percentage describes. Those details are not reported in the registry record.

Finally, statistical interpretation depends on more than a named endpoint. The analysis plan, uncertainty estimates, population definitions, and multiplicity approach help readers judge how stable and interpretable a result is. The record lists three outcome measures and does not report analyses. This study therefore highlights why complete registry reporting is important: design, outcome, missingness, and analysis details together determine what a result can support.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting the primary outcome is that its numerical result is not reported in the registry record. No outcome count, denominator, percentage, or confidence interval is available, so neither the observed level of suppression nor its precision can be assessed.

The single-group design has no assigned control group. It can describe outcomes in the enrolled group but does not permit a direct comparison with a different care strategy. Allocation is listed as not applicable and masking as none. The record does not report a comparative or adjusted analysis that would address differences over time or other influences on outcomes.

Enrollment was 27, but the record does not state how many participants contributed six-month endpoint data. It notes that data were not collected for participants lost to follow-up or death due to the COVID pandemic, without reporting the number affected or how missing outcomes were treated. This leaves uncertainty about the analysis population and the extent to which missingness could affect a reported proportion.

The registry lists three outcome measures and no analyses, and it does not describe the statistical analysis plan, multiplicity handling, or sample-size justification. It also does not report the endpoint result after the subsequent six months of traditional-clinic care. These reporting gaps limit assessment of both the primary result and the wider care sequence. Finally, the safety entries lack reported detail on event timing and attribution, which limits causal interpretation.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program — NCT04650269.
• Registry record last updated 2025-01-08; status last verified 2024-12.
• Results first posted 2025-01-08.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT04650269 is a completed Phase 4, single-group study sponsored by the University of Miami. The registry lists enrollment of 27, allocation as not applicable, and no masking. The study concerns rapid onsite ART initiation and HIV care at the IDEA Syringe Services Program for people who inject drugs living with HIV.

The arm description specifies six months of onsite care including Biktarvy followed by six months of standard care at a traditional clinic. The primary endpoint is viral suppression at six months, defined as less than 200 copies/ml in blood. Its numerical result is not reported in the registry record.

The record notes that data were not collected for participants lost to follow-up or death due to the COVID pandemic. It lists three serious adverse events, three deaths, and no participants affected by other adverse events in the Rapid ART Group. These entries are descriptive and do not establish causation. Analysis methods, analysis populations, and the sample-size justification are not reported in the registry record.